Melinta Therapeutics (MLNT) to Release Quarterly Earnings on Wednesday

Share on StockTwits

Melinta Therapeutics (NASDAQ:MLNT) is scheduled to be announcing its earnings results before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of ($2.88) per share for the quarter.

Melinta Therapeutics (NASDAQ:MLNT) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($2.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.72) by $0.38. The business had revenue of $14.08 million during the quarter, compared to the consensus estimate of $16.83 million. Melinta Therapeutics had a negative net margin of 161.27% and a negative return on equity of 61.13%. On average, analysts expect Melinta Therapeutics to post $-10 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of NASDAQ:MLNT opened at $3.85 on Tuesday. The company has a current ratio of 1.40, a quick ratio of 1.06 and a debt-to-equity ratio of 0.87. The stock has a market cap of $43.82 million, a P/E ratio of -0.22 and a beta of 4.31. Melinta Therapeutics has a 52 week low of $1.62 and a 52 week high of $28.25. The company has a 50 day moving average price of $4.97.

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. downgraded shares of Melinta Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Friday, June 14th. Cantor Fitzgerald set a $15.00 price target on shares of Melinta Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 19th. ValuEngine upgraded shares of Melinta Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, July 22nd. WBB Securities downgraded shares of Melinta Therapeutics from a “speculative buy” rating to a “hold” rating in a research report on Thursday, June 20th. Finally, Gabelli restated a “sell” rating on shares of Melinta Therapeutics in a research report on Thursday, June 20th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Melinta Therapeutics currently has a consensus rating of “Hold” and an average target price of $28.00.

About Melinta Therapeutics

Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.

Read More: Cost of equity and a company’s balance sheet

Earnings History for Melinta Therapeutics (NASDAQ:MLNT)

Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Horizon Global  Stock Price Up 6.1%
Horizon Global Stock Price Up 6.1%
Secure Energy Services Inc  Receives C$10.06 Average Price Target from Brokerages
Secure Energy Services Inc Receives C$10.06 Average Price Target from Brokerages
Citi Trends, Inc.  Given Average Recommendation of “Strong Buy” by Analysts
Citi Trends, Inc. Given Average Recommendation of “Strong Buy” by Analysts
Tyme Technologies  Trading Up 6%
Tyme Technologies Trading Up 6%
CommVault Systems, Inc.  Expected to Post Earnings of $0.28 Per Share
CommVault Systems, Inc. Expected to Post Earnings of $0.28 Per Share
Brokerages Anticipate Applied Optoelectronics Inc  to Announce -$0.24 EPS
Brokerages Anticipate Applied Optoelectronics Inc to Announce -$0.24 EPS


© 2006-2019 Ticker Report